Targeted disruption of tumor vasculature via polyphenol nanoparticles to improve brain cancer treatment
Source abstract
Abstract
Despite being effective for many other solid tumors, traditional anti-angiogenic therapy has been shown to be insufficient for the treatment of malignant glioma. Here, we report the development of polyphenol nanoparticles (NPs), which not only inhibit the formation of new vessels but also enable targeted disruption of the existing tumor vasculature. The NPs are synthesized through a combinatory iron-coordination and polymer-stabilization approach, which allows for high drug loading and intrinsic tumor vessel targeting. We study a lead NP consisting of quercetin and find that the NP after intravenous administration preferentially binds to VEGFR2, which is overexpressed in tumor vasculature. We demonstrate that the binding is mediated by quercetin, and the interaction of NPs with VEGFR2 leads to disruption of the existing tumor vasculature and inhibition of new vessel development. As a result, systemic treatment with the NPs effectively inhibits tumor growth and increases drug delivery to tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. Malignant gliomas in 2005: where to GO from here?10.1001/jama.293.5.615 ↗
2. Current therapeutic paradigms in glioblastoma10.2174/157488710790820544 ↗
3. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium10.1002/cncr.23741 ↗
4. Novel delivery strategies for glioblastoma10.1097/PPO.0b013e318244d8ae ↗
5. Antiangiogenic Therapy of High-Grade Gliomas10.1159/000467379 ↗
6. Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis10.3390/cancers11111723 ↗
7. New Directions in Anti-Angiogenic Therapy for Glioblastoma10.1007/s13311-016-0510-y ↗
8. Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment10.3390/jcm9010084 ↗
9. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study10.1038/sj.bjc.6600885 ↗
10. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent10.1038/sj.bjc.6600992 ↗
11. ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors
12. Natural polyphenols in cancer therapy10.3109/10408363.2011.631268 ↗
13. Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy10.1021/acs.jmedchem.6b01026 ↗
14. Are polyphenol antioxidants at the root of medicinal plant anti-cancer success?10.1016/j.jep.2018.09.037 ↗
15. Polyphenol-Containing Nanoparticles: Synthesis, Properties, and Therapeutic Delivery10.1002/adma.202007356 ↗
16. Metal–phenolic network-based nanocomplexes that evoke ferroptosis by apoptosis: promoted nuclear drug influx and reversed drug resistance of cancer10.1021/acs.chemmater.9b03042 ↗
17. One-step assembly of coordination complexes for versatile film and particle engineering10.1126/science.1237265 ↗
18. Magnetic metal phenolic networks: expanding the application of a promising nanoprobe to phosphoproteomics research10.1039/D0CC04615A ↗
19. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy10.1038/s41467-019-11719-3 ↗
20. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles10.1038/s41467-018-04315-4 ↗
21. Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel10.1038/s41551-020-0597-7 ↗
22. Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging10.1021/acsnano.5b07573 ↗
23. Estimation of total phenolic content and other oxidation substrates in plant tissues using Folin-Ciocalteu reagent10.1038/nprot.2007.102 ↗
24. Supramolecular nanogel-based universal drug carriers formed by “soft–hard” co-assembly: accurate cancer diagnosis and hypoxia-activated cancer therapy
25. Therapeutic potential of quercetin: new insights and perspectives for human health10.1021/acsomega.0c01818 ↗
26. A glucose/oxygen-exhausting nanoreactor for starvation-and hypoxia-activated sustainable and cascade chemo-chemodynamic therapy10.1002/smll.202000897 ↗
27. Switching apoptosis to ferroptosis: metal–organic network for high-efficiency anticancer therapy10.1021/acs.nanolett.6b04060 ↗
28. Photoacoustic Therapy for Precise Eradication of Glioblastoma with a Tumor Site Blood–Brain Barrier Permeability Upregulating Nanoparticle10.1002/adfm.201808601 ↗
29. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential10.1080/13543784.2019.1650019 ↗
30. Current status and future directions of anti-angiogenic therapy for gliomas10.1093/neuonc/nov180 ↗
31. Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model10.7150/thno.24395 ↗
32. Anti-angiogenesis property by quercetin compound targeting VEGFR2 elucidated in a computational approach
33. VEGF-receptor signal transduction10.1016/S0968-0004(03)00193-2 ↗
34. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress10.1038/nature03952 ↗
35. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016)10.1080/13543776.2017.1344215 ↗
36. Quercetin inhibits vascular endothelial growth factor-induced choroidal and retinal angiogenesis in vitro10.1159/000369824 ↗
37. Cell-permeable iron inhibits vascular endothelial growth factor receptor-2 signaling and tumor angiogenesis10.18632/oncotarget.11689 ↗
38. Nanoparticles’ interactions with vasculature in diseases10.1039/C9CS00309F ↗
39. Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE-cadherin10.1038/ncomms2655 ↗
40. Targeting Endothelial Cell Junctions with Negatively Charged Gold Nanoparticles10.1021/acs.chemmater.8b00840 ↗
41. Anti-edema and antioxidant combination therapy for ischemic stroke via glyburide-loaded betulinic acid nanoparticles10.7150/thno.35791 ↗
42. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice
43. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines10.1016/j.ccr.2006.03.030 ↗
44. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria10.1038/sj.onc.1210949 ↗
45. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance10.1073/pnas.0702596104 ↗
46. Ex Vivo Dynamics of Human Glioblastoma Cells in a Microvasculature-on-a-Chip System Correlates with Tumor Heterogeneity and Subtypes
47. Nanoparticles promote in vivo breast cancer cell intravasation and extravasation by inducing endothelial leakiness10.1038/s41565-018-0356-z ↗
48. Bioavailability of dietary polyphenols: factors contributing to their clinical application in CNS diseases10.1016/j.neuint.2015.07.003 ↗
49. Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective10.2147/IJN.S131973 ↗
50. Nanoparticle formulations to enhance tumor targeting of poorly soluble polyphenols with potential anticancer properties10.1016/j.semcancer.2017.06.010 ↗
51. High drug-loading nanomedicines: progress, current status, and prospects10.2147/IJN.S132780 ↗
52. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses10.1158/1078-0432.CCR-06-2854 ↗
53. Polymeric nanoparticles for drug delivery to the central nervous system10.1016/j.addr.2011.12.006 ↗
54. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma10.1073/pnas.1304504110 ↗